Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.60    0.00 (0.00%)
Bid:
0.55
Ask:
0.65
Spread: 0.10 (18.182%)
Market Cap: £2.72m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director Dealing

12 Dec 2017 10:17

RNS Number : 0902Z
Physiomics PLC
12 December 2017
 

12th December 2017

Physiomics plc

("Physiomics") or ("the Company")

 

Director Dealing

 

The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share:

 

Director

Number of shares sold

Sale price per share

Dr J Millen, CEO

240,000

8.3p

Dr C Chassagnole, COO

600,000

8.3p

 

Following the sales of shares, the total holdings of each Director of the Company will be as follows:

 

Dr Paul Harper 525,707

Dr Jim Millen 444,641

Dr Christophe Chassagnole 417,008

 

The total number of shares in issue remains 58,785,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Millen

2

Reason for the notification

a)

Position/status

Director, CEO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

240,000

d)

Aggregated information

- Aggregated volume

- Price

 

240,000

At 8.3p per share

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christophe Chassagnole

2

Reason for the notification

a)

Position/status

Director, COO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

600,000

d)

Aggregated information

- Aggregated volume

- Price

 

600,000

At 8.3p

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

 

 

 

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford

+44 (0) 161 832 2174

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHTTBMTMBBBBIR
Date   Source Headline
19th Jan 201810:20 amRNSHolding(s) in Company
17th Jan 20183:52 pmRNSHolding(s) in Company
13th Dec 20172:06 pmRNSResult of AGM
12th Dec 201710:17 amRNSDirector Dealing
6th Dec 20173:00 pmRNSIssue of Equity
30th Nov 20171:38 pmRNSShare Price Movement
28th Nov 20177:00 amRNSClinical Project Completion and Services Agreement
9th Nov 20177:00 amRNSDispatch of Annual Report and Shareholder Circular
16th Oct 20177:00 amRNSFinal Results
2nd Oct 20177:00 amRNSCompany Update
31st Jul 20177:00 amRNSTwo New Pre-Clinical Contracts
6th Jun 20177:00 amRNSPhysiomics to Attend PAGE 2017
24th May 20177:00 amRNSUpdate: Two Further Extension Projects
5th May 20177:00 amRNSPhysiomics to Present at BioTrinity 2017
24th Mar 201711:15 amRNSInterim Results Statement
11th Jan 20177:00 amRNSCompany Update
6th Jan 20177:00 amRNSConfirmation of Award of Innovate UK Grant
22nd Dec 20163:31 pmRNSDirector Dealing
22nd Dec 20167:00 amRNSIssue of Options
16th Dec 20161:00 pmRNSResult of AGM
5th Dec 20167:00 amRNSPayment for in-silico modelling of inhibitor
23rd Nov 20167:00 amRNSPosting of Financial Results and Notice of AGM
22nd Nov 20167:00 amRNSProvisional Award of Innovate UK Grant
27th Oct 20163:00 pmRNSFinal Results for the year ended 30 June 2016
26th Oct 20167:00 amRNSPresentation at Conference on Pharmacometrics
25th Oct 20167:00 amRNSDirectorate Change
28th Sep 20167:00 amRNSAdvisor Changes
21st Sep 20167:00 amRNSPlacing and Update on Acquisition
7th Sep 201612:19 pmRNSResult of GM
22nd Aug 20167:00 amRNSNotice of General Meeting
18th Aug 20167:00 amRNSSigning of Share Purchase Agreement with BioMoti
16th Aug 20161:05 pmRNSAdvisor Changes
16th May 20167:00 amRNSExtensions for Virtual Tumour Project
3rd May 20167:00 amRNSAppointment of part-time Head of Finance
18th Apr 20169:02 amRNSPhysiomics Appoints New Chief Executive Officer
6th Apr 201610:15 amRNSVirtual Tumour Developments Presentation at AACR
4th Apr 201612:12 pmRNSNew Speciality Pharma Customer for new Indication
31st Mar 20167:01 amRNSInterim Results Statement
31st Mar 20167:00 amRNSHeads of Terms with BioMoti and Board Changes
22nd Dec 201512:08 pmRNSIssue of Options
22nd Dec 20157:00 amRNSNew Speciality Pharma Customer for New Indication
18th Dec 201510:57 amRNSPlacing
14th Dec 201510:29 amRNSResult of General Meeting
4th Dec 201511:38 amRNSResult of AGM
27th Nov 20154:15 pmRNSNotice of General Meeting
10th Nov 20157:00 amRNSFinal Results
6th Nov 20157:00 amRNSStrategic Update
12th Oct 20157:00 amRNS4th Large Pharma Customer for Virtual Tumour
9th Oct 20157:00 amRNSProject extension with global pharma company
4th Aug 20157:01 amRNSProf. Mark Middleton appointed to Physiomics SAB

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.